Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non-Current Assets (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Non-Current Assets data on record, last reported at $53.4 million in Q4 2025.

  • For Q4 2025, Non-Current Assets fell 14.13% year-over-year to $53.4 million; the TTM value through Dec 2025 reached $209.5 million, down 16.05%, while the annual FY2025 figure was $53.4 million, 14.13% down from the prior year.
  • Non-Current Assets reached $53.4 million in Q4 2025 per LCTX's latest filing, up from $47.4 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $63.6 million in Q1 2023 and bottomed at $5.7 million in Q4 2022.
  • Average Non-Current Assets over 5 years is $57.5 million, with a median of $62.6 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: surged 1003.08% in 2023, then dropped 24.77% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $62.9 million in 2021, then tumbled by 90.98% to $5.7 million in 2022, then soared by 1003.08% to $62.6 million in 2023, then dropped by 0.57% to $62.2 million in 2024, then dropped by 14.13% to $53.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $53.4 million in Q4 2025, $47.4 million in Q3 2025, and $47.0 million in Q2 2025.